Scienture partners with distributor to sell REZENOPY naloxone spray to 2,000 US opioid treatment clinics

Scienture Holdings entered an exclusive sales, marketing and distribution deal for REZENOPY naloxone spray with a partner focused on addiction treatment centers.

The deal creates a dedicated channel across about 2,000 U.S. opioid treatment program clinics and other addiction treatment networks.

Scienture will continue selling REZENOPY outside this segment through wholesalers, GPOs, other distributors and institutional customers.

IQVIA data for MAT July 2026 shows the U.S. naloxone market at about $140 million in annual sales across 9,800,000 units.